India-based pharmaceutical giant Cipla Ltd, headquartered in Mumbai, Maharashtra, has reported a 30.12% year-on-year (YoY) surge in net profit for the fourth quarter of FY25, reaching ₹1,221.84 crore. The company’s strong Q4 performance is backed by an 8.5% increase in sales revenue. Cipla also announced a total dividend of ₹16 per share, including a special dividend to mark its 90th anniversary.
Cipla Ltd, one of India’s leading pharmaceutical companies headquartered in Mumbai, Maharashtra, reported a 30.12% year-on-year increase in its consolidated net profit for the fourth quarter of FY25. The profit stood at ₹1,221.84 crore, compared to ₹939.04 crore in the same quarter of the previous fiscal year.
The revenue from sales also showed a positive trend, growing by 8.5% to ₹6,597.72 crore in Q4FY25, up from ₹6,082.37 crore in Q4FY24. The pharmaceutical segment alone contributed ₹6,503.63 crore, registering an 8.5% increase from the ₹5,996.38 crore reported a year earlier. Cipla’s new ventures recorded a significant 35.44% YoY rise in revenue, reaching ₹288.48 crore.
In a celebratory move, marking its 90th year of operations, Cipla’s Board of Directors declared a final dividend of ₹13 per equity share and an additional special dividend of ₹3 per share. This brings the total dividend to ₹16 per equity share of face value ₹2 each for FY25.
The company’s strong quarterly performance and dividend announcement underline its sustained growth momentum in both core pharmaceutical operations and new business ventures.
